دورية أكاديمية
أعرض في EDS

Biomarker Analysis from a Phase I/Ib Study of Regorafenib and Nivolumab in Mismatch Repair-Proficient Advanced Refractory Colorectal Cancer.

التفاصيل البيبلوغرافية
العنوان: Biomarker Analysis from a Phase I/Ib Study of Regorafenib and Nivolumab in Mismatch Repair-Proficient Advanced Refractory Colorectal Cancer.
المؤلفون: Kim DW; Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA., Kim YC; Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL 33612, USA., Kovari BP; Department of Pathology, Moffitt Cancer Center, Tampa, FL 33612, USA., Martinez M; Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA., Miao R; Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA., Yu J; Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA., Mehta R; Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA., Strosberg J; Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA., Imanirad I; Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA., Kim RD; Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA.
المصدر: Cancers [Cancers (Basel)] 2024 Jan 28; Vol. 16 (3). Date of Electronic Publication: 2024 Jan 28.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مستخلص: Previously, we reported the modest but durable anticancer activity of regorafenib/nivolumab in mismatch repair-proficient (pMMR) refractory colorectal cancer in our I/Ib study. Our finding suggests the necessity of biomarkers for better selection of patients. Baseline clinical and pathological characteristics, blood and tumor samples from the patients in the trial were collected and evaluated to discover potential biomarkers. The obtained samples were assessed for immunohistochemistry, ELISA and RNA sequencing. Their correlations with clinical outcome were analyzed. A high albumin level was significantly associated with improved progression-free survival (PFS), overall survival (OS) and disease control. Non-liver metastatic disease showed prolonged PFS and OS. Low regulatory T-cell (Treg) infiltration correlated with prolonged PFS. Low MIP-1β was associated with durable response and improved OS significantly. Upregulation of 23 genes, including CAPN9, NAPSA and ROS1, was observed in the durable disease control group, and upregulation of 10 genes, including MRPS18A, MAIP1 and CMTR2, was associated with a statistically significant improvement of PFS. This study suggests that pretreatment albumin, MIP-1β, non-liver metastatic disease and Treg infiltration may be potential predictive biomarkers of regorafenib/nivolumab in pMMR colorectal cancer. Further studies are needed to confirm these findings.
References: Br J Cancer. 2021 May;124(11):1803-1808. (PMID: 33828254)
Adv Exp Med Biol. 2020;1231:23-32. (PMID: 32060843)
EClinicalMedicine. 2023 Apr 06;58:101917. (PMID: 37090438)
Eur J Cancer. 2022 Nov;176:171-180. (PMID: 36252287)
Immunol Rev. 2011 May;241(1):260-8. (PMID: 21488902)
Sci Immunol. 2020 Oct 2;5(52):. (PMID: 33008914)
Front Mol Biosci. 2022 Dec 02;9:1039121. (PMID: 36533070)
Lancet Oncol. 2022 May;23(5):659-670. (PMID: 35427471)
Anticancer Res. 2018 Dec;38(12):6771-6782. (PMID: 30504389)
Cancers (Basel). 2021 Mar 19;13(6):. (PMID: 33808696)
Tumour Biol. 2018 Nov;40(11):1010428318810059. (PMID: 30419802)
Clin Cancer Res. 2021 Apr 15;27(8):2139-2147. (PMID: 33495314)
N Engl J Med. 2020 Dec 3;383(23):2207-2218. (PMID: 33264544)
N Engl J Med. 2015 Jun 25;372(26):2509-20. (PMID: 26028255)
Cell Oncol (Dordr). 2020 Jun;43(3):409-420. (PMID: 32166582)
Cancers (Basel). 2022 Dec 22;15(1):. (PMID: 36612059)
Cancer Immunol Immunother. 2022 Feb;71(2):399-415. (PMID: 34181042)
Int J Cancer. 2010 Jun 1;126(11):2635-43. (PMID: 19856313)
J Clin Oncol. 2020 Jan 1;38(1):11-19. (PMID: 31725351)
Nat Med. 2021 Jan;27(1):152-164. (PMID: 33398162)
NPJ Precis Oncol. 2022 Apr 7;6(1):23. (PMID: 35393553)
Eur J Cancer. 2022 Jul;169:93-102. (PMID: 35526308)
Am J Kidney Dis. 1998 Dec;32(6 Suppl 4):S118-25. (PMID: 9892378)
J Clin Oncol. 2020 Jun 20;38(18):2053-2061. (PMID: 32343640)
Front Pharmacol. 2022 Aug 11;13:950831. (PMID: 36034778)
Int Immunol. 2007 Apr;19(4):345-54. (PMID: 17329235)
J Pharm Biomed Anal. 2019 Jul 15;171:204-211. (PMID: 31009875)
Nat Med. 2016 Jun;22(6):679-84. (PMID: 27111280)
Cancers (Basel). 2022 Jul 15;14(14):. (PMID: 35884500)
Front Oncol. 2021 Nov 24;11:694664. (PMID: 34900664)
معلومات مُعتمدة: P30-CA076292 United States CA NCI NIH HHS
فهرسة مساهمة: Keywords: biomarker; colorectal cancer; mismatch repair-proficient; nivolumab; regorafenib
تواريخ الأحداث: Date Created: 20240210 Latest Revision: 20240212
رمز التحديث: 20240212
مُعرف محوري في PubMed: PMC10854756
DOI: 10.3390/cancers16030556
PMID: 38339307
قاعدة البيانات: MEDLINE
الوصف
تدمد:2072-6694
DOI:10.3390/cancers16030556